A DOUBLE BLIND, CONTROLLED WITH PLACEBO EXTENSION STUDY OF MK-0633 CARRIED OUT IN ADULT PATIENTS WITH CHRONIC ASTHMA (EXTENSION TO PROTOCOL 007)

MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2008年12月16日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•The patient has successfully completed until Visit 16, including the latter, of Protocol 007.
•The patient is able to understand the study procedures and agrees to participate in the study by providing written informed consent.

•The patient presented a serious laboratory or clinical adverse event related to the drug during their participation in Protocol 007.
•The patient has presented clinically significant changes in his general medical condition since enrollment in Protocol 007 that, according to the investigator´s medical criteria, would exclude the patient from participating or completing the study. Such changes may include, but are not limited to, an unstable disease newly diagnosed clinically from the ophthalmological, neurological, hepatic, renal, connective tissue, genitourinary, gastrointestinal, cardiovascular or hematological systems. In addition, any disease that could be life-threatening (for example, ventricular arrhythmia, neoplasia [incompletely cured or treated in the last three months], poorly controlled diabetes mellitus), would prevent the patient from participating in the study.

发起方

MERCK SHARP & DOHME PERU S.R.L.,